The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|March 14, 2012
Two More Earn AAHRPP Accreditation
Advertisement
All told, 243 organizations have now earned accreditation, including institutions in 46 states, the District of Columbia, Puerto Rico, Canada, China, India, Korea, and Singapore.
The latest accreditations come as AAHRPP marks 10 years since the issuance of the first accreditation standards in 2002. "Our progress has been remarkable," said Marjorie A. Speers, Ph.D., AAHRPP president and CEO. "A decade ago, accreditation was virtually unheard of. Today, it is synonymous with high-quality research and ethical treatment of research participants."
Speers gives much of the credit for AAHRPP's success to the research enterprise. "Accreditation has taken hold because the research community genuinely cares about protecting participants," she said. "Despite the challenges of the past decade, the research community has stood firm and embraced the rigors of accreditation."
Accreditation is available to US and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. The list of accredited organizations includes community and teaching hospitals; VA facilities, universities; institutional review boards; research institutes and contract research organizations.
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5